Breast Plenary Abstracts<br />How Do These Studies Impact Clinical Practice Today and in the Years Ahead?<br />

Presented By Eric Winer at 2014 ASCO Annual Meeting

First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC)

Presented By Eric Winer at 2014 ASCO Annual Meeting

N9831/B-31 Disease-Free Survival

Presented By Eric Winer at 2014 ASCO Annual Meeting

Pathologic Response in Neo-ALTTO

Presented By Eric Winer at 2014 ASCO Annual Meeting

CALGB 40601 (TH vs TL vs THL)

Presented By Eric Winer at 2014 ASCO Annual Meeting

Adjuvant Lapatinib (ALTTO) Schema

Presented By Eric Winer at 2014 ASCO Annual Meeting

Disease Free Survival (DFS) Analysis

Presented By Eric Winer at 2014 ASCO Annual Meeting

Disease Free Survival By Hormone Receptor Status

Presented By Eric Winer at 2014 ASCO Annual Meeting

Slide 9

Presented By Eric Winer at 2014 ASCO Annual Meeting

Overall Survival (OS) Analysis

Presented By Eric Winer at 2014 ASCO Annual Meeting

Main Differences In AEs By Treatment Arm

Presented By Eric Winer at 2014 ASCO Annual Meeting

Thoughts About ALTTO

Presented By Eric Winer at 2014 ASCO Annual Meeting

Further Implications for Research and Practice

Presented By Eric Winer at 2014 ASCO Annual Meeting

Why Improvement in Pathologic Complete Response May Not Lead to Change in DFS

Presented By Eric Winer at 2014 ASCO Annual Meeting

Randomized Comparison of Adjuvant Aromatase Inhibitor <br />Exemestane plus Ovarian Function Suppression<br /> vs Tamoxifen plus Ovarian Function Suppression<br />in Premenopausal Women <br />with Hormone Receptor Positive Early Breast Cancer: <br />Joint Analysis of IBCSG TEXT and SOFT

Presented By Eric Winer at 2014 ASCO Annual Meeting

Study Schemas (Total N=4690)

Presented By Eric Winer at 2014 ASCO Annual Meeting

Improved DFS with Exemestane + OFS vs Tamoxifen + OFS

Presented By Eric Winer at 2014 ASCO Annual Meeting

Sites of First Failure

Presented By Eric Winer at 2014 ASCO Annual Meeting

Overall Survival at 5 Years

Presented By Eric Winer at 2014 ASCO Annual Meeting

Women Who Did Not Receive Chemotherapy

Presented By Eric Winer at 2014 ASCO Annual Meeting

Selected Adverse Events

Presented By Eric Winer at 2014 ASCO Annual Meeting

Adverse Events and QOL

Presented By Eric Winer at 2014 ASCO Annual Meeting

Slide 23

Presented By Eric Winer at 2014 ASCO Annual Meeting

Does Ovarian Suppression Add To Tamoxifen In Premenopasual Women?<br />Findings FromThe LHRH Meta-Analysis<br />

Presented By Eric Winer at 2014 ASCO Annual Meeting

Slide 25

Presented By Eric Winer at 2014 ASCO Annual Meeting

Primary End Point: Disease-Free Survival<br />No Significant Difference Between TAM and ANA

Presented By Eric Winer at 2014 ASCO Annual Meeting

Is OS + AI The New Standard of Care?

Presented By Eric Winer at 2014 ASCO Annual Meeting

What To Consider When You Go Home (1)

Presented By Eric Winer at 2014 ASCO Annual Meeting

What To Consider When You Go Home (2)

Presented By Eric Winer at 2014 ASCO Annual Meeting

Thank you

Presented By Eric Winer at 2014 ASCO Annual Meeting